Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Bender Robert & Associates

Bender Robert & Associates increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,956 shares of the life sciences company's stock after purchasing an additional 4,337 shares during the quarter. Illumina makes up approximately 0.8% of Bender Robert & Associates' investment portfolio, making the stock its 24th largest position. Bender Robert & Associates' holdings in Illumina were worth $3,170,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ILMN. Fourth Dimension Wealth LLC purchased a new position in shares of Illumina during the 4th quarter worth $40,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina during the fourth quarter worth about $45,000. Assetmark Inc. raised its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the period. Lee Danner & Bass Inc. acquired a new position in Illumina in the 4th quarter valued at about $48,000. Finally, Rakuten Securities Inc. boosted its holdings in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Ankur Dhingra acquired 6,100 shares of Illumina stock in a transaction dated Monday, May 12th. The stock was acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.17% of the company's stock.

Analyst Ratings Changes

ILMN has been the topic of several recent analyst reports. Citigroup decreased their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Stephens restated an "overweight" rating and issued a $105.00 price objective on shares of Illumina in a report on Tuesday, May 20th. Piper Sandler lowered their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Robert W. Baird dropped their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Finally, Royal Bank Of Canada decreased their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $126.94.

Illumina Stock Up 0.9%

Shares of Illumina stock traded up $0.79 on Wednesday, reaching $90.26. 2,019,090 shares of the company were exchanged, compared to its average volume of 2,278,827. The stock's 50 day moving average price is $79.75 and its 200-day moving average price is $101.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The company has a market cap of $14.29 billion, a P/E ratio of -14.87, a price-to-earnings-growth ratio of 1.77 and a beta of 1.33.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same quarter in the previous year, the business posted $0.98 EPS. The firm's revenue was down 1.4% on a year-over-year basis. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.